-
Professor Jiang Zefei: Waving goodbye to the old years, striding to welcome the new dynasty, breast cancer diagnosis and treatment extended to diversification Review of the annual progress of breast cancer treatment in 2022
Time of Update: 2023-02-01
The conference reviewed the important academic progress of breast cancer in 2022, and launched the update of the 2023 version of the Chinese Society of Clinical Oncology Breast Cancer (CSCO BC) Diagnosis and Treatment Guidelines.
-
【Lancet】The cure rate is nearly 50%! The survival rate is over 90%! A team from the University of Hong Kong has discovered a new strategy for the treatment of locally advanced liver cancer
Time of Update: 2023-02-01
Recently, the pioneering Phase II clinical study of triple mode therapy (START-FIT) conducted by the Department of Surgery and Clinical Oncology, School of Clinical Medicine, The University of Hong Kong, Li Ka Shing School of Medicine, found that nearly 50% of patients with inoperable locally advanced liver cancer can be cured by this innovative method.
-
Perioperative clinical trials and development of new drugs for the treatment of gliomas
Time of Update: 2023-02-01
Study results Perioperative clinical trials for gliomas range widely, including phase 0, perioperative, biopsy surgery, neoadjuvant therapy, and timing (Figure 1).
Study results Perioperative clinical trials for gliomas range widely, including phase 0, perioperative, biopsy surgery, neoadjuvant therapy, and timing (Figure 1).
-
Relationship between the degree of tumor resection of pHGG and the survival rate of children
Time of Update: 2023-02-01
Research methods The authors collected data from randomized clinical trials and cohort studies related to pHGG in databases such as PubMed, EBMR, Embase, and MEDLINE, and included a total of 37 articles, including 1387 children with pHGG.
-
"Phenanthrene" long vision - case sharing ADT treatment should be "deep ketone reduction", triptorelin hypoketone performance is particularly excellent
Time of Update: 2023-02-01
As one of the most common malignant tumors in men in the world, the incidence of prostate cancer in China has increased year by year in recent years, which is seriously threatening the health of middl
-
CDTM uses natural killer cells to develop next-generation cellular immunotherapies
Time of Update: 2023-02-01
are important innate immune cells in the human body, which can kill tumor cells without pre-sensitization, and CAR-NK is expected to become one of the most anticipated engineered cell therapies after the success of CAR-T cell therapyReferencesLiu, S, Nguyen, K, Park, D, Wong, N, Wang, A, Zhou, Y.
-
【Talking about bowel cancer】Professor Hu Hanguang | wonderful attack: Join hands to overcome difficulties and focus on the diagnosis and treatment of MDT for colorectal cancer
Time of Update: 2023-02-01
【Rambling on bowel cancer】Wonderful |Professor Wang Xicheng: Scientific prevention and treatment, strategizing, focusing on the diagnosis and treatment and thinking of hereditary colorectal cancerThis platform is designed to deliver more medical information to healthcare professionals.
-
Blood Yuqin Song's team at Peking University discovered a potential new treatment for diffuse large B-cell lymphoma
Time of Update: 2023-02-01
iNatureIn the Phase 3 POLARIX study (NCT03274492), polatuzumab vedotin plus rituximab plus cyclophosphamide, doxorubicin, and prednisone (Pola-R-CHP) had a similar safety profile in previously untreat
-
Non-invasive detection of GBM nanoparticle materials based on photoacoustic imaging technology
Time of Update: 2023-02-01
of the Department of Chemical and Biomolecular Engineering of the National University of Singapore constructed nanoparticle TCFNP@iRGD for photoacoustic imaging of GBM in a mouse model derived from intracranial transplantation of glioma patient cells (GPDCs), and the material showed excellent GBM detection performance in vitro and in vivo.
-
Professor Ma Jun: 2022 important clinical research on head and neck tumors - attenuation and personalization are highlights
Time of Update: 2023-02-01
A study published in 2022 by Professor Ma Jun's team from the Sun Yat-sen University Cancer Center found that for the above-mentioned low-risk nasopharyngeal carcinoma patients, radiotherapy alone was not inferior to concurrent chemoradiotherapy [3].
-
2022 SABCS Professor Wang Shu: Analyze the therapeutic value of novel ADCs in HER2-low expression breast cancer, and look forward to the new pattern of treatment in the future
Time of Update: 2023-02-01
*For medical professionals onlyThe new ADC has a wide range of layouts and is expected to fully cover people who benefit from breast cancer. With the establishment of the efficacy of antibody-drug con
-
FDA was approved to | annual inventory (middle) of breast cancer and gynecologic oncology
Time of Update: 2023-02-01
S. Food and Drug Administration (FDA) approved fam-trastuzumab deruxtecan nxki (DS-8201, T-DXd) for patients with unresectable or metastatic HER2-positive adult breast cancer who had received anti-HER2 therapy in prior systemic therapy or anti-HER2 therapy in neoadjuvant or adjuvant therapy and developed disease recurrence during treatment or within 6 months of completion of treatment。On May 4, 2022, the U.
-
Professor Fang Shencun and Professor Shen Hua talked about the latest research results of 3-day continuous intravenous pumping of recombinant human vascular endostatin to help elderly NSCLC patients benefit!
Time of Update: 2023-02-01
*For medical professionals onlyRecombinant human vascular endostatin 3-day continuous intravenous pumping combined with platinum-containing double-agent chemotherapy adds new evidence!As the malignant
-
IDH1 mutant glioma stem cells secrete G-CSF to improve the effect of immunotherapy
Time of Update: 2023-02-01
The results of this study showed that immunotherapy (TK/Flt3L) was effective in mIDH1 glioma due to the reprogramming of myeloid cells infiltrated in the tumor microenvironment.
-
Professor Liu Jian: New ADC drugs have created a new situation, and HER2 low thinking is in the ascendant
Time of Update: 2023-02-01
Tolaney has a negative view, mainly in the following aspects:(1) No unique clinicopathological featuresA study published in Lancet Oncol in 2021 combined patient data from four prospective neoadjuvant therapy clinical trials (including a total of 3512 patients, of which 2310 were included in the analysis) [4], aiming to compare the clinical and pathological features of HER2-low expression and HER2 0 breast cancer, found that HER2-low breast cancer included more HR-positive patients and fewer G3 patients.
-
With the three-pronged approach, all the metastases of advanced gastric cancer disappeared
Time of Update: 2023-02-01
, An abscopal effect in a gastric cancer patient treated with combined chemoimmunotherapy and palliative radiotherapy, Immunotherapy (2022)Zengtao Bao, et al.
-
Clinical application of BRAF V600 mutation frequency and its inhibitors in glioma patients
Time of Update: 2023-02-01
In 93 studies on BRAFi, data were collected on 394 patients, including 241 children, 144 adults, and 9 NR.
In 93 studies on BRAFi, data were collected on 394 patients, including 241 children, 144 adults, and 9 NR.
-
A new approach to treating COVID-19: IL-6 antagonists target cytokine storm – treating different diseases: severe COVID and tumor immunotherapy-associated pneumonia
Time of Update: 2023-02-01
Director Zhou Chengzhi, a respiratory oncologist at the National Center for Respiratory Medicine, said: IL-6 antagonist, which has been used in the treatment of tumor by immune checkpoint inhibitors, caused by severe immune adverse reactions, especially drugs often used during immune pneumonia, in some severe patients caused by COVID-19, for cytokine storm, clinical practice has proved to be a good treatment.
-
Ideas collide, big coffee gathers to talk about hot spots The Chinese edition of NCCN's "Bladder Cancer" was released
Time of Update: 2023-02-01
// Recently, the release of the Chinese version of the NCCN "Bladder Cancer" guidelines was successfully held in the cloud. Professor Guo Jun of Peking University Cancer Hospital and Professor He Zhi
-
2023 CASH Professor Zhu Xiaofan: Immunotherapy brings hope for survival for childhood acute lymphoblastic leukemia patients, and the treatment of relapsed patients still needs to be explored
Time of Update: 2023-02-01
Yimaitong: At this year's China Hematology Development Conference, you shared the latest progress in pediatric hematology, what progress is worth paying attention to in the diagnosis and treatment of pediatric ALL?Professor Zhu XiaofanThe progress on ALL in children at the 2022 ASH Conference mainly includes three aspects: new mechanisms (omic type mapping and prognostic molecular markers), new strategies (chemotherapy optimization, targeted therapy and cellular immunotherapy) and new technologies (artificial intelligence and high-throughput drug screening).
